Drug Trial Radar · NCT05101187
Olorofim Aspergillus Infection Study
Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
225
Actual
Start
Apr 29, 2022
Primary completion
Nov 18, 2025
Study completion Mar 19, 2026
Sponsor
- Lead sponsor
- F2G LtdIndustry
- Sponsor type
- Industry
- Collaborators
- IQVIA Pty Ltd; Shionogi
- First posted
- Nov 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with IFD caused by proven IA or probable lower respiratory tract disease Aspergillus species (invasive aspergillosis, IA).
Conditions
- Invasive Aspergillosis
Interventions
OlorofimDrug
Loading Dose: 5 tablets (150 mg) to be taken twice daily at a 12-hour (± 1 hour) interval on Day 1 Maintenance Dose: 3 tablets (90 mg) to be taken twice daily at 12-hour (± 1 hour) intervals from Day 2 until Day 84 (± 7 days)
AmBisome®Drug
Initial course of at least 10 days of AmBisome® administered daily at a dose of 3 mg/kg by IV infusion over a 30- to 60-minute period or according to local guidelines Administration of SOC will follow international, national, or local guidelines and product labelling.
Primary outcomes
What the sponsor says the trial is designed to measure.
- All-cause mortalityTime frame: Treatment Day 42
Locations
143 sites in 21 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
City of Hope National Medical Center
Duarte, California
University of California Davis Health System
Sacramento, California
UCSF Helen Diller Medical Center at Parnassus Heights
San Francisco, California
University of Florida
Gainesville, Florida
Augusta University
Augusta, Georgia
University of Chicago Medical Center
Chicago, Illinois
University of Kansas Medical Center
Kansas City, Kansas
The Johns Hopkins Hospital
Baltimore, Maryland
NIH Clinical Center ,NIAID,NIH
Bethesda, Maryland
Massachusetts General Hospital
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
University of Minnesota
Minneapolis, Minnesota
Mayo Clinic - Rochester
Rochester, Minnesota
Washington University School of Medicine
St Louis, Missouri
Clairvoyant Research Group, LLC
Las Vegas, Nevada
Rutgers RWJMS
New Brunswick, New Jersey
Weill Cornell Medicine NY Presbyterian Hospital
New York, New York
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Duke Department of Medicine Infectious Diseases Division
Durham, North Carolina
OU Health OU Medical Center
Oklahoma City, Oklahoma
University of Pittsburgh Medical Center Health System
Pittsburgh, Pennsylvania
Houston Methodist
Houston, Texas
Fred Hutchinson Cancer Center
Seattle, Washington
Royal NorthShore Hospital
Saint Leonards, New South Wales, Australia
Royal Brisbane & Women's Hospital
Herston, Queensland, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Royal Melbourne Hospital
Parkville, Victoria, Australia
Fiona Stanley Hospital
Murdoch, Western Australia, Australia
AZ Sint-Jan
Bruges, Belgium
Hôpital Erasme
Brussels, Belgium
UZ Leuven
Leuven, Belgium, Belgium
Universitair Ziekenhuis Gent
Ghent, Gent, Belgium
Hospital Felício Rocho
Belo Horizonte, Minas Gerais, Brazil
Santa Casa de Misericórdia de Belo Horizonte
Belo Horizonte, Minas Gerais, Brazil
Santa Casa de Misericórdia de Passos
Passos, Minas Gerais, Brazil
Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer
Curitiba, Paraná, Brazil
Irmandade da Santa Casa de Misericórdia de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Hospital São Lucas da PUCRS
Porto Alegre, Rio Grande do Sul, Brazil
Showing 40 of 143 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.